According to the Technical University of Munich (TUM), around 1.5 million people worldwide are diagnosed with prostate cancer each year. A team at TUM has developed a new class of radiopharmaceuticals, known as radiohybrid PSMA ligands (rhPSMA), designed to improve the visualization of tumors and metastases, which is critical for successful treatment. Conventional imaging techniques like CT and MRI can struggle to distinguish small tumors or early-stage metastases from surrounding tissue, but these new molecules aim to address that limitation.

The radiopharmaceuticals work by carrying a radioactive diagnostic isotope, such as fluorine-18, and binding with high precision to prostate cancer cells that express a specific protein called prostate-specific membrane antigen (PSMA). Once bound, the cells are made visible using positron emission tomography (PET). TUM reported that the compound acts as a molecular probe to detect disease-related changes within the body.

Hans-Jürgen Wester, former Professor of Pharmaceutical Radiochemistry at TUM, said the team's vision was to create a tool broadly useful in nuclear medicine imaging that could also lead to targeted therapies. He developed the underlying radiohybrid technology with Alexander Wurzer, then a doctoral researcher. Wurzer noted that his doctoral research built on extensive experience in prostate cancer research and allowed him to refine existing molecular scaffolds. He emphasized the value of close collaboration between the research group and TUM University Hospital, from basic research through to clinical development.

Matthias Eiber, Professor of Nuclear Medicine at TUM University Hospital, said that accurately mapping tumors is essential for patients. He recalled being impressed by the clarity and precision of images acquired with the new compound, which could visualize even very small tumor lesions. The researchers developed the compound as a diagnostic radiopharmaceutical in collaboration with Eiber's team.

TUM filed a patent application for the invention in 2017 at Wester's initiative. Wurzer initially worried the process might delay his doctoral research, as results could not be published until after the application was filed, but those concerns proved unfounded as the process was completed relatively quickly. The university's technology transfer office, TUM ForTe Patents and Licenses, supported the researchers by advising on intellectual property, providing funding, and negotiating licensing agreements. TUM reports around 180 inventions to ForTe each year, with roughly 80 resulting in patent applications, most with support from Bayerische Patentallianz (BAYPAT).

BAYPAT concluded a licensing agreement for the radiohybrid technology with Scintomics, a TUM spin-off founded by Wester in 2006. Scintomics initially developed automated production systems for radiopharmaceuticals before expanding into developing its own compounds. The company translated the academic invention into a technology suitable for industrial development, laying the groundwork for clinical and regulatory progress. Scintomics then entered a sublicense agreement with the British pharmaceutical company Blue Earth Diagnostics, which took over clinical and regulatory development and guided the radiopharmaceutical through to market approval.

The diagnostic radiopharmaceutical received regulatory approval in the United States in 2023, followed by Taiwan and South Korea in 2025, making it available for clinical use. Eiber said the diagnostic agent provides physicians with a new level of precision, enabling them to tailor treatment plans to individual patients and avoid unnecessary therapies.

Wurzer highlighted another key advantage: the robustness and efficiency of the production process. Working with radioactive isotopes is a race against time, he said, but the compound's easy synthesis and high scalability make it possible to manufacture reliably and in large quantities. Wurzer now oversees technology transfer at TUM University Hospital's Department of Nuclear Medicine, where he supports the development of production methods for radiopharmaceuticals targeting various cancers.

Research into radiohybrid technology is ongoing. The radiopharmaceutical is structured so that its molecular backbone can attach to a therapeutic isotope, such as lutetium-177, instead of a diagnostic one. This could allow it to deliver radiation directly to cancer cells and destroy them while largely sparing healthy tissue. Wurzer said the technology was designed for both diagnosis and potential therapy, a principle known as theranostics. A therapeutic application has not yet been approved, but several clinical trials are currently underway.

Wurzer considers patent protection a crucial factor in the technology's success. He said a patent provides the foundation for companies to invest in the extensive development and regulatory work required to bring a new technology to patients, and without that protection, many inventions would never make their way into widespread clinical use.